Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Fasinumab in Chronic Low Back Pain with Hip or Knee Osteoarthritis
2017-001943-12Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic low back pain (CLBP), hip osteoarthritis and knee osteoarthritis (OA) comparing Fasinumab with Placebo (2 arms). Primary endpoint: Change in daily average low back pain intensity. Started Jan 2018; status: terminated.
02
Drugs
fasinumab
03
Conditions
chronic low back pain (CLBP)hip osteoarthritisknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2017-001943-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001943-12.